JUL 11, 2020 1:07 PM PDT

New drug combo could improve immunotherapy for SCCOHT ovarian cancer

Research published recently in PLOS ONE reports on SP-2577, a drug that could help girls and young women plagued with a type of ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). According to researcher Dr. Jeffrey Trent, who has been working on this topic at the Translational Genomics Research Institute (TGen) for years, SP-2577 could tap the immune system to help combat SCCOHT.

In the study, The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer, the researcher team proposes a two-fold attack, combining SP-2577, or Seclidemstat, with another immunotherapeutic compound. 

"Immunotherapy is the future of cancer treatment. Our combination of drugs should promote an immune response in an ovarian cancer that usually does not respond well to immunotherapies," said lead author Dr. Raffaella Soldi, a TGen Research Associate Professor. "One drug opens a biological gate, while the other drug helps push immune cells through the gate to attack the cancer."

SP-2577 works by inhibiting a protein called LSD1, which is known to play a role in SCCOHT ovarian cancer, among other cancer types. 

"We suggest in this paper that LSD1 inhibition should improve the immune-therapy response in these tumors. This treatment is exquisitely dependent on the mutation found by Dr. Trent and his group. Without that mutation, this treatment would not work," commented senior author Dr. Sunil Sharma, TGen Deputy Director of Clinical Sciences. 

Dr. Sharma is referring to a previous discovery that a single mutation in a gene called SMARCA4 triggered SCCOHT. Interestingly, this gene had been shown before to be associated with lung, brain, and pancreatic cancer.  "The correlation between mutations in SMARCA4 and the development of SCCOHT is simply unmistakable," explained Dr. Trent in reference to this finding.

The SP-2577 and Pembrolizumab combination is soon to be tested in clinical trials for patients with SCCOHT ovarian cancer. 

Sources: PLOS ONE, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 10, 2020
Cancer
What fireflies' bioluminescence can teach us about mitochondria and cancer
AUG 10, 2020
What fireflies' bioluminescence can teach us about mitochondria and cancer
Researchers have developed a technique to measure mitochondria activity in cells using a molecule from fireflies. The me ...
SEP 08, 2020
Cancer
The story of a very scary protein
SEP 08, 2020
The story of a very scary protein
New research from biochemists at the University of Alberta has identified a protein that triggers the growth of aggressi ...
SEP 12, 2020
Cancer
Treating cancer with the botanical andrographis
SEP 12, 2020
Treating cancer with the botanical andrographis
A study from City of Hope published in the journal Carcinogenesis reports that the use of the natural botanical And ...
SEP 16, 2020
Cancer
I'm addicted to the sun, are you?
SEP 16, 2020
I'm addicted to the sun, are you?
New research published in the Journal of Investigative Dermatology reports evidence that some people are geneticall ...
OCT 05, 2020
Cancer
Fighting mitochondrial terminal exhaustion
OCT 05, 2020
Fighting mitochondrial terminal exhaustion
New findings reported in Nature Immunology highlight how the tumor microenvironment attacks the mitochondria of T l ...
OCT 25, 2020
Cell & Molecular Biology
Revealing More About the Genetics of Ewing Sarcoma
OCT 25, 2020
Revealing More About the Genetics of Ewing Sarcoma
Ewing sarcoma is a rare kind of cancer that tends to impact young people and occurs in bones or the tissue around them. ...
Loading Comments...